Bisantrene (C007B-336283)

Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases . Bisantrene is a substrate of MDR1In VitroBisantrene promots DNase I cleavage at oligopurine-oligopyrimidine tracts and slightly reduces the cleavage activity at alternating purine-pyrimidine sequences. ?/nBisantrene is an inhibitor of [ 3 H]uridine incorporation into RNA and [ 3 H]thymidine incorporation into DNA. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoBisantrene is an antitumor agent active against a number of experimental tumors, including P388 leukemia, L1210 leukemia, Lieberman plasma cell tumor, B16 melanoma, colon tumor 26, and Ridgway osteogenic sarcoma. ?/nBisantrene is effective over a dose range of 1.56 to 150 mg/kg depending upon the frequency, route, and schedule of the treatment and the tumor model used. ?/nBisantrene (25, 50 and 100 mg/kg; i.p.; once) pretreats with macrophages shows antitumor effect to mice with P815 tumor cells injection. ?/nBisantrene (10-150 mg/kg; i.v.; once) dose-dependently induces leukopenia in Neo mice. B cells and macrophages are targets for bisantrene toxicity. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Topoisomerase II.

Specifications and Purity: ≥98%

Molecular Formula: C22H22N8

Molecular Weight: 398.5

PubChem CID: 5351322

Isomeric SMILES: C1NC(=NC1)N/N=C/C2=C3C(=C(C4=CC=CC=C24)/C=N/NC5=NCCN5)C=CC=C3